BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
about
Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Biomarker in Colorectal Cancer.Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study.Important molecular genetic markers of colorectal cancer.BRAF in metastatic colorectal cancer: the future starts now.Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors.Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma.Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational studyClinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by ComprehenBRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?Emerging treatment options for BRAF-mutant colorectal cancer.Exome-wide somatic mutation characterization of small bowel adenocarcinoma.New life for retrospective study in the precision oncology era.Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al.KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.Colorectal cancer genomics and designing rational trials.Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver CancerThe Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer
P2860
Q35877954-6645BA37-5850-48C5-8010-6CA3C4DB2044Q36006605-352E8459-0330-42D7-9DEB-200440CD91DBQ36115580-038E0D93-F7DE-4741-8BAD-CB46C6269868Q37114675-8C47C3FE-FB3C-4808-9EB1-67187D1E991DQ37241845-5340771D-AB5D-4547-9776-2F1BA5A76057Q37619856-CD3259C6-DEBF-4FFA-8A18-26E092067E60Q38652005-12DBD41A-7614-4E05-9356-F0DBD5FFADB0Q38787278-CDC7A281-0B96-4769-BFB4-35BF98627D22Q38826084-7C28454B-17AD-463A-922E-9268ABAA53E8Q38941928-599D06B8-46D2-4357-87ED-35007C0C93E7Q39223563-05106013-B19D-4867-A77B-203DE1E5EC56Q40209192-AFD3A782-BA10-42D1-9103-1CD1F23971EBQ41091941-FE29B1BF-F23E-4A65-825C-1FC02E872A6FQ41622213-D9F4CCCC-7C21-45E5-9BBD-02FC8CC59BB3Q42690646-D1529654-6B37-497B-ABD6-A5E51367065FQ47109685-D2E3ED7D-EDC1-4DDF-B2A8-F6E69F616EE4Q47767987-54E6938A-1D01-4968-B99F-39AF6D4F2C6CQ50897558-38C67FF9-FA59-42AF-86B0-9DA776BBBB35Q52599786-943439DD-483C-4D1B-BA41-29252B2B6D88Q52664402-8968B56E-625F-48A0-A0A8-11C962AE4A37Q54247863-E2B34231-5B5E-4900-BA3A-417426096281Q54247867-1B28CE57-348B-4490-B5A4-04176FF6C1B0Q55131841-E8075059-62E8-4292-8A70-8618B782A043Q55306266-A0F1223E-0A1A-4B20-96FD-A9B3EFE4209EQ56969146-A33D8EA1-64E4-404F-AE13-9114E4275C5AQ58799989-8186992B-02AD-4862-A590-A50ACF45C3B0
P2860
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
BRAF codons 594 and 596 mutati ...... cancer at favorable prognosis.
@ast
BRAF codons 594 and 596 mutati ...... cancer at favorable prognosis.
@en
type
label
BRAF codons 594 and 596 mutati ...... cancer at favorable prognosis.
@ast
BRAF codons 594 and 596 mutati ...... cancer at favorable prognosis.
@en
prefLabel
BRAF codons 594 and 596 mutati ...... cancer at favorable prognosis.
@ast
BRAF codons 594 and 596 mutati ...... cancer at favorable prognosis.
@en
P2093
P2860
P50
P356
P1433
P1476
BRAF codons 594 and 596 mutati ...... cancer at favorable prognosis.
@en
P2093
C Antoniotti
C Lauricella
R Berenato
P2860
P304
P356
10.1093/ANNONC/MDV290
P50
P577
2015-07-07T00:00:00Z